XpresSpa Group said this week its XpresCheck division is expanding its rapid COVID-19 testing efforts by offering travelers another option, the Accula SARS-CoV-2 test from Thermo Fisher Scientific.
The testing protocol has received an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) and provides results in 30 minutes. Unlike antigen-based rapid tests, the Accula tests use the polymerase chain reaction (RT-PCR) process, thought to be more accurate and often required for travel to some regions and countries.
XpresCheck will introduce the Accula tests with pilots programs at John F. Kennedy International Airport (JFK) and George Bush Intercontinental Airport (IAH) in Houston next week.
“PCR testing continues to be the key that unlocks access to more travel destinations, so we are pleased to bring another convenient rapid PCR test for travelers to get test results back at the airport versus waiting for days,” said Doug Satzman, XpresSpa CEO. “We are proud to be playing our part in supporting the return of air travel to pre-pandemic levels by making sure both airport employees and travelers feel safe and confident when they come to the airport.”
